Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #1 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of GLA on Human Volunteers

NCT01397604
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GLA-AF, GLA-SE, Squalene
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

NCT02339155
View directory record Official record
Conditions
Infections, Bacterial
Interventions
AVA, Raxibacumab, Diphenhydramine
Biological · Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
573 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Edgewater, Florida • Overland Park, Kansas • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 30, 2026, 10:56 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

NCT07525544
View directory record Official record
Conditions
HIV Infections
Interventions
VH4770359, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

NCT01484964
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
Interventions
ASP015K
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

Oral Cladribine in Early Multiple Sclerosis (MS)

NCT00725985
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Rebif® new formulation (RNF)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of ALA-1000

NCT04122755
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
ALA-1000, buprenorphine sublingual film
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

NCT02792699
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ABP 798, Rituximab (US), Rituximab (EU)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
27
States / cities
Tuscaloosa, Alabama • Los Angeles, California • Thousand Oaks, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

NCT04903093
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2, Abrocitinib Suspension F3, Abrocitinib Suspension F4, Abrocitinib Suspension F5, Abrocitinib Suspension F6, Famotidine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 30, 2026, 10:56 PM EDT
Terminated Phase 1 Interventional

ONC201 in Pediatric H3 K27M Gliomas

NCT03416530
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
Interventions
Dordaviprone (ONC201)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 30, 2026, 10:56 PM EDT
Active, not recruiting Phase 2 Interventional

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

NCT05889273
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
ML-004 (IR)/(ER) tablet
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
12 Years to 46 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
18
States / cities
Dothan, Alabama • Phoenix, Arizona • Glendale, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 30, 2026, 10:56 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

NCT06109441
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ALTB-268
Biological
Lead sponsor
AltruBio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
23
States / cities
San Diego, California • Littleton, Colorado • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 10:56 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism

NCT05543928
View directory record Official record
Conditions
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
Interventions
CTAP101, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Columbus, Ohio • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 30, 2026, 10:56 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

NCT03191383
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Newton, Kansas • Syracuse, New York • Ellensburg, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 30, 2026, 10:56 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Postprandial Response to Fruit Juice

NCT07103083
View directory record Official record
Conditions
Blood Glucose, Blood Insulin
Interventions
Beverage 1, Beverage 2, Beverage 3, Beverage 4, Beverage 5, Beverage 6
Dietary Supplement
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

NCT03529773
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Formulation A, Formulation B, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
40
States / cities
Mobile, Alabama • Anaheim, California • La Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 2 Interventional

A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

NCT01320527
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Nutriceutical formulation, Placebo
Dietary Supplement · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Naples, Florida • Baltimore, Maryland • Ayer, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare a New Eye Drop Formulation With Refresh Contacts®

NCT01844388
View directory record Official record
Conditions
Contact Lens Lubrication
Interventions
carboxymethylcellulose based eye drop formula, carboxymethylcellulose sodium based eye drop solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Bloomington, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 30, 2026, 10:56 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

NCT06295159
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab, Ipilimumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acidophilus Pearls Fecal Recovery Study

NCT02001610
View directory record Official record
Conditions
Survival of Probiotics During GI Transit, GI Symptoms
Interventions
Acidophilus pearls, Hard shell gelatin capsules
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 30, 2026, 10:56 PM EDT
Terminated Phase 2 Interventional

IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)

NCT04575610
View directory record Official record
Conditions
COVID-19
Interventions
PF-06650833, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

NCT03875729
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
teplizumab, Placebo
Biological
Lead sponsor
Provention Bio, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
34
States / cities
San Diego, California • San Francisco, California • Walnut Creek, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

NCT05496231
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation, Gardasil 9
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years to 26 Years · Female only
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
39
States / cities
San Diego, California • Wheat Ridge, Colorado • Coral Gables, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)

NCT06611033
View directory record Official record
Conditions
Healthy
Interventions
V118C, V118, PREVNAR 20™, Saline
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Hallandale, Florida • Hollywood, Florida • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 30, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

NCT04696393
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Mitapivat tablet
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 30, 2026, 10:56 PM EDT